Cwm LLC Has $33.48 Million Position in Pfizer Inc. (NYSE:PFE)

Cwm LLC increased its position in Pfizer Inc. (NYSE:PFEFree Report) by 7.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,206,466 shares of the biopharmaceutical company’s stock after acquiring an additional 79,627 shares during the period. Cwm LLC’s holdings in Pfizer were worth $33,479,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $32,000. VisionPoint Advisory Group LLC grew its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the fourth quarter valued at approximately $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.86.

Get Our Latest Research Report on PFE

Pfizer Price Performance

Shares of NYSE PFE traded up $0.43 during midday trading on Wednesday, reaching $27.41. 29,817,777 shares of the company traded hands, compared to its average volume of 33,368,410. The firm has a market cap of $155.32 billion, a PE ratio of -456.76, a PEG ratio of 1.06 and a beta of 0.70. The stock’s 50-day simple moving average is $27.58 and its 200-day simple moving average is $27.73. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $39.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue was down 19.5% on a year-over-year basis. During the same period last year, the business earned $1.23 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were paid a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.13%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.